KSKarin Stenderup

Karin Stenderup

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karin Stenderup has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 October 2013
      • Vol. 12  (10) , 1156-62

    Valrubicin activates PKCa in keratinocytes: a conceivable mode of action in treating hyper-proliferative skin diseases.

    by Ina Groenkjaer Laugesen, Eva Hauge, Stine Maria Andersen, Karin Stenderup, Elisabeth De Darkó, Tomas Norman Dam, Cecilia Rosada

    Valrubicin is a semisynthetic anthracycline developed as an anti-cancer drug able to ameliorate psoriasis and non-melanoma skin cancer (NMSC) by topical application in animal models. Valrubicin decreases cell proliferation, and induces apoptosis; however its mode of action is still unknown. Valrubicin localizes in the cytoplasm and its valerate moiety resembles diacylglycerol, an activator of protein kinase C (PKC) α, which belongs to the PKC family of cytoplasmic serine/threonine protein kinases. PKCα is observed in the suprabasal layers of normal skin and is associated to keratinocyte growth arrest and differentiation processes. In hyper-proliferative skin diseases the presence of PKCα is altered. The aim of the present study was to investigate valrubicin's mode of action in keratinocytes by studying its possible effect on PKCα activation. PKCα's characteristic to translocate from the cytoplasm to the cellular membrane when activated was assessed by measuring the amount of PKCα in the soluble and membrane-bound protein fractions isolated from valrubicin stimulated keratinocytes and by visualizing PKCα in stimulated cells over time. Downstream signaling was investigated by measuring the amount of phosphorylated Myristoylated Alanine-rich C-kinase substrate (MARCKS) and extracellular signal-regulated kinases (ERK) 1/2 of valrubicin-stimulated keratinocytes. To investigate whether there was a direct interaction between valrubicin and PKCα, an activity assay employing purified PKCα protein was used. Valrubicin activates PKCα in vitro as shown by PKCα's translocation and phosphorylation of downstream signaling molecules. Valrubicin stimulates PKCα activity and downstream signaling which may contribute to its beneficial effect in psoriasis and NMSC.

  • Open Access

    Topical application of valrubicin has a beneficial effect on developing skin tumors

    by Stine M. Andersen, Cecilia Rosada, Frederik Dagnaes-Hansen, Ina G. Laugesen, Elisabeth de Darkó, Tomas N. Dam, Karin Stenderup

    Valrubicin is a second generation anthracycline characterized by an excellent safety profile presenting no skin toxicity or necrosis upon contact. In its current liquid formulation (Valstar™; Indevus Pharmaceuticals, Lexington, MA), it is approved solely for the treatment of bladder cancer. Recently, valrubicin was incorporated in a cream formulation rendering this drug available for topical application. The cytostatic property of valrubicin can, thus, be employed for treating hyperproliferative skin diseases as was recently described for psoriasis. In the present study, the effect of topical application of valrubicin was investigated in skin tumor development; we hypothesized that valrubicin may be employed in treating actinic keratosis, a hyperproliferative skin condition that may transform into malignancy. A two-stage chemical mouse skin carcinogenesis model that represents the multistage etiology of human skin cancer—from developing papillomas to squamous cell carcinoma (SCC) was used. Moreover, two human skin SCC cell lines: DJM-1 and HSC-1 were cultured, to further investigate the effect of valrubicin in vitro. Cell viability was assessed by adenosine triphosphate presence, proliferation as proliferative cell nuclear antigen expression and apoptosis as cytokeratin 18 cleavage, caspase activation, poly-adenosine diphosphate-ribose-polymerase cleavage and bax and bcl-2 regulation. Valrubicin significantly inhibited tumor formation in the mouse skin carcinogenesis model and significantly decreased cell viability of the cultured human skin SCC cells. In both mouse skin and SCC cells, proliferation was significantly decreased. Apoptosis was significantly increased in SCC cells but unchanged in the treated mouse skin at study completion. This study demonstrated that topical application of valrubicin has a beneficial effect in treating developing skin tumors.


  • Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model

    by K. Stenderup, C. Rosada, A. Worsaae, F. Dagnaes-Hansen, T. Steiniche, E. Hasselager, L.F. Iversen, S. Zahn, H. Wöldike, H. Lindgreen Holmberg, et al.

    Background Interleukin (IL)‐20 is a recently discovered cytokine displaying increased levels in psoriatic lesions. Interestingly, IL‐20 levels decrease with antipsoriatic treatment, correlating with clinical improvement. However, the role of IL‐20 in the aetiology of psoriasis is unknown. Objectives In this study, we investigate the effects both of blocking IL‐20 signalling in psoriatic plaques and of adding IL‐20 to nonlesional psoriasis skin. Methods We employed the human skin xenograft transplantation model in which psoriatic plaques and nonlesional keratome skin biopsies obtained from donors with moderate to severe plaque psoriasis were transplanted on to immuno‐deficient mice. The transplanted mice were treated with anti‐IL‐20 antibodies or recombinant human IL‐20. Results We demonstrate that blocking IL‐20 signalling with anti‐IL‐20 antibodies induces psoriasis resolution and inhibits psoriasis induction. We also demonstrate that continuous IL‐20 infusion, together with injection of additional nonactivated leucocytes, promotes induction of psoriasis in nonlesional skin from patients with psoriasis. Conclusions The results suggest that IL‐20 plays a critical role in the induction and maintenance of psoriasis, and IL‐20 is suggested as a new possible specific target in psoriasis treatment.


    • 1 September 2008
      • Vol. 170  (36) , 2777-81

    [Interleukin-20--a new target in psoriasis treatment].

    by Karin Stenderup, Cecilia Rosada, Tomas Norman Dam

    Interleukin-20 (IL-20) is suggested as a new target in psoriasis treatment. It was first described in 2001, and the potential role of this cytokine in psoriasis was suggested because mice which were over-expressing IL-20 developed a psoriasis-like phenotype of the skin. Subsequently, IL-20 expression levels were found to be increased in psoriasis skin, and it was observed that these levels normalized upon psoriasis treatment. In the psoriasis xenograft transplantation model, administration of IL-20 to non-lesional psoriasis skin transplanted onto immune-deficient mice demonstrated that IL-20 was involved in the psoriasis induction. More interestingly, improvement of psoriasis was induced by blocking IL-20 signaling.